Valuation: Abpro Corporation

Market Cap 1.29M 1.12M 1.04M 956K 1.8M 124M 1.84M 12.4M 4.88M 60.68M 4.83M 4.73M 209M P/E 2024
-2.41x
P/E 2025 -3.27x
Enterprise Value 1.37M 1.19M 1.1M 1.02M 1.91M 132M 1.96M 13.17M 5.18M 64.45M 5.13M 5.02M 222M EV / Sales 2024
497x
EV / Sales 2025 -
Free-Float
83.91%
Yield 2024 *
-
Yield 2025 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.29M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +0.05%-0.02%+65.98%+98.43% 27.07B
Weighted average by Cap. -0.05%-0.27%+79.44%+123.32%

Financials

2024 2025
Net sales 183K 160K 148K 136K 256K 17.62M 262K 1.76M 694K 8.63M 687K 672K 29.71M -
Net income -7.23M -6.32M -5.83M -5.38M -10.13M -696M -10.36M -69.71M -27.42M -341M -27.16M -26.56M -1.17B -2.89M -2.53M -2.33M -2.15M -4.05M -279M -4.14M -27.87M -10.96M -136M -10.86M -10.62M -470M
Net Debt 478K 418K 385K 355K 670K 46.03M 685K 4.61M 1.81M 22.54M 1.8M 1.76M 77.61M 80K 69.91K 64.51K 59.46K 112K 7.7M 115K 771K 303K 3.77M 300K 294K 12.99M
Logo Abpro Corporation
Abpro Holdings, Inc. is a biotechnology company. The Company is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration (AMD) and diabetic macular edema (DME). These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. It plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Employees
-